RESVERLOGIX (TSX: RVX) IS A LATE-STAGE BIOTECHNOLOGY COMPANY WITH A NOVEL EPGENIC APPROACH TO REDUCING THE INCIDENCE OF MAJOR ADVERSE CARDIAC EVENTS (MACE) IN HIGH-RISK CARDIOVASCULAR PATIENTS. LEAD DRUG APABETALONE IS FULLY ENROLLED IN A PHASE 3 CLINICAL TRIAL CALLED BETONMACE.

Resverlogix is developing safe, affordable, first-in-class epigenetic therapeutics for people with heart disease, diabetes, chronic kidney disease and other life-threatening illnesses. Lead drug candidate apabetalone is in a fully enrolled Phase 3 clinical trial, BETonMACE.

MULTI-MODAL PATHWAY MECHANISM

Apabetalone, a bromodomain extra-terminal (BET) protein inhibitor regulates the expression of genes and restores the function of pathways underlying the pathogenesis of cardiovascular disease, type 2 diabetes mellitus and chronic kidney disease.

- Vascular Inflammation: Reductions in mediators that promote inflammation of the vasculature
- Reverse Cholesterol Transport Pathway: Increased Apo-A-I, positive effects on lipid content of HDL
- Complement Pathway: Reductions in components and function of the complement cascade
- Coagulation Pathway: Reductions in components of the coagulation cascade
- Vascular Calcification: Reductions in mediators that promote calcium deposition in the vasculature
- Metabolism: Delayed and reduced oral glucose absorption and endogenous production

Contact Information:
- Email: ir@resverlogix.com
- Phone: 403.254.9252
- Website: www.resverlogix.com
- Twitter: @Resverlogix_RVX
Fact Sheet
April 2019

Epigenetics

While most people are familiar with the inheritance of genes via DNA from one generation to the next, the activity of these genes is actually determined by epigenetics, which literally means "on top of" genetics. DNA is considered the hardware of the human body, while epigenetics can be referred to as the software. DNA contains the code that tells our cells what to do, and this coded message is the same in every cell and does not change with time. However, our cells do not behave in the exact same way across time, particularly when disease is involved. Epigenetic changes to the DNA allow the message in the genes to be turned up or down like a dimmer switch, telling the cells which products to make more, or less of. During this process the DNA is not altered. The epigenetic control over the genetic message in the DNA underlies many diseases, and for this reason, epigenetics has become an exciting forefront for the discovery of new medicines.

APABETALONE (RVX-208) CLINICAL TRIAL HISTORY

- Phase 3 BETonMACE trial commenced Q4/15 for high-risk CVD patients with type 2 diabetes mellitus and low HDL.
- BETonMACE is fully enrolled.
- Primary endpoint: time to first occurrence of Major Adverse Cardiovascular Events (MACE).
- Based on mechanistic data, we believe apabetalone.
- Treatment, or select BET inhibition, attenuates the pathological process that contributes to disease initiation and progression.

News Highlights

April 1, 2019 - RVX Announces $15.1 Million of Private Placements.

April 1, 2019 - RVX Cognition Substudy of BETonMACE Phase 3 CVD Trial Presented at the International Conference on Alzheimer’s and Parkinson’s Diseases.

March 27, 2019 - RVX Announces Ninth Positive Data Safety Monitoring Board Recommendation for Phase 3 BETonMACE Study of Apabetalone.

Analysts

Roth Capital Partners: Jotin Marango, MD, PhD.
Van Leeuwenhoek Research: Marcel Wijma, MSc.
Zacks: John Vandermosten, CFA.

Financial Profile

- Shares O/S (MM): ~200
- Share Price: ~$3.28
- 52 week low/high: $1.11/$4.31.
- Total Cash Raised (MM): ~$484.2

Notes:
*As at 3-APRIL 2019
*All figures in CAD$